Replies to post #37171 on Biotech Values

[DewDiligence]

>I don't think NM-283 is necessarily dead meat if the riba combo bombs, either. It will just make things much more difficult.<

What IDIX investors should be rooting for is an outcome where ribavirin is allowed to be given with NM283 in phase-3 but ends up adding little or nothing to the mix. I.e., the best outcome in phase-3 would be superiority of NM283+pegifn vs SoC and non-inferiority of NM283+pegifn vs NM283+riba+pegifn.

[dewophile]

i have a funny feeling the dose used was not reflective of pharmacological dosing in human trials
i am not a pharmacologist, and don;t knwo how animal dosing translates to human, but it appears that concentrations were used that are comparable with 500 mg PER KG daily doses of nm-283 (i assume this was because idix had published on comparable doses from their pre-clinical studies). as we know 200-800 mg/DAY are given clinically
just a thought/guess